http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2718250-A2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1a34d7d2e0d09a58cb7bf4a04c81162e
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02P20-584
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J2231-32
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J23-94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C17-278
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J31-0258
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J35-023
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J31-0257
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J23-745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C17-275
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C19-01
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B01J23-745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B01J31-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C17-275
filingDate 2012-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0f4619b5726ebd09b5f1dcfdccc7cac3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ad30cc1a42f392a92e4b6faaf7773002
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c4566c3c492bb87dcf71041e3aa1870
publicationDate 2014-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-2718250-A2
titleOfInvention Method for mitigating the formation of by-products during the production of haloalkane compounds
abstract Disclosed is a process for the manufacture of haloalkane compounds, and more particularly, an improved process for the manufacture of the compound 1,1,1,3,3-penta-chloropropane (HCC-240fa), which mitigates the formation of by-products from vinyl chloride (CH 2 =CHCl). The present invention is also useful in the manufacture of other haloalkane compounds such as HCC-250 and HCC-360. One embodiment of the invention comprises a method for mitigating 1,1,3,3,5,5-hexachloropentane and 1,1,1,3,5,5-hexachloropentane formation in the HCC-240fa manufacturing process, in which FeCl 3 , is introduced to a reactor only after the start-up phase has ended and a continuous operation has started. In a preferred embodiment, "pre-chelated" FeCl 3 , which is concentrated in a catalyst recovery column, is introduced to reactor after the continuous operation has started.
priorityDate 2011-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5943
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6214
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID230114263
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID167469
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24380
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226411070
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419547008
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23268888
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6338
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426105809
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419485362
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8289
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419546195
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID31373
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6901
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID231468712
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6535
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226408156
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID19376168
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID68030
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID31357
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID425966242
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226412159
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419518999
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID231468166
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419527288
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419527028
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226506238
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID411290149
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226411886
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23925
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419530947
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID21946199
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415861274
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419519744
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID407874179
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID412447562
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414867054
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7845
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226459856
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3084393
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419491185
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10546
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419614438
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419516895
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6327
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419524917
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10541
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226408552
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID422608614
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11203
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID53980744
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226479477
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID230114264

Total number of triples: 80.